A public-private precompetitive consortium aims to expand the number of known GPCR structures from 26 to over 200.
Merck KGaA enters the tankyrase race; Pluristem joins with Case Western to test its new cell therapy; Astellas
A 3D neuronal culture model of Alzheimer's disease is much improved over earlier models, but researchers disagree on whether it is close enough to human disease for use in drug discovery.
A new campaign to petition Congress to increase NIH funding has the backing of several academic heavyweights but stops short of defining how the money would be spent.
Two awards totaling over $300,000 will fuel SQZ Biotech's scale-up of its microfluidics-based CellSqueeze platform that delivers bioactive materials directly into cells.
OncoTherapy Science has a potent TOPK inhibitor in a liposomal formulation that avoids the toxicity of other cytokinesis-targeted compounds.
A paper-based diagnostic using RNA switches could provide an easily distributed, rapid test for infectious diseases in point-of-care settings.
The once discarded target GPR120 has led to the discovery of an entirely new class of fatty acids that could restore insulin sensitivity in patients with diabetes.
Indiana University researchers have found a route to building blood vessels by developing a protocol to generate mass quantities of endothelium-forming cells.
The NIH is committing $70 million to creating new adjuvants that can work with different types of vaccines and wants industry to get involved.
Karolinska's new deputy vice chancellor, Alexander von Gabain, has plans to break down silos and breed new mindsets to maximize the institute's translational potential.
HemoShear's in vitro tumor model shows a new application for its tissue modeling technology and could open it to business from oncology companies.